What's New on the FDA Drugs Site
September 27, 2013
- Chronic Fatigue Syndrome and Myalgic Encephalomyelitis (CFS and ME) Stakeholder Teleconference – October 16, 2013
- FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning
- FDA alerts patients and health care providers not to use budesonide solution from The Compounding Shop
New and Generic Drug Approvals
September 26, 2013
Drug Name | Active Ingredient | Dosage Form/Route | Sponsor | Submission Type |
---|---|---|---|---|
Mestinon | pyridostigmine bromide | Syrup;Oral | Valeant Pharm Intl | Manufacturing Change or Addition |
Pur-Wash | purified water | Solution;Ophthalmic | Niagara Pharms | Manufacturing Change or Addition |
Remodulin | treprostinil | Injectable;Iv (Infusion)-Sc | United Therap | Labeling Revision |
Somavert | pegvisomant | Injectable;Subcutaneous | Pharmacia and Upjohn | Manufacturing Change or Addition |
Terazol 3 | terconazole | Suppository;Vaginal | Janssen Pharms | Labeling Revision |
Terazol 3 | terconazole | Cream;Vaginal | Janssen Pharms | Labeling Revision |
Terazol 7 | terconazole | Cream;Vaginal | Janssen Pharms | Labeling Revision |
Tobi | tobramycin | Solution;Inhalation | Novartis Pharms | Labeling Revision |
Tygacil | tigecycline | Injectable;Iv (Infusion) | Pf Prism Cv | Labeling Revision |
Vyfemla | ethinyl estradiol; norethindrone | Tablet;Oral-28 | Lupin Ltd | Approval |
Zoloft | sertraline hydrochloride | Tablet;Oral | Pfizer | Manufacturing Change or Addition |
No comments:
Post a Comment